{"filings":[{"id":787011,"accession_number":"0001493152-26-026696","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-06-01T23:40:29+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma uses presentation to discuss Harmonic Phase 2 trial of LP-300","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 on June 1, 2026, regarding LP-300 in Harmonic Phase 2 trial.","No specific trial results or financial data disclosed in the 8-K filing itself.","Investors must review the presentation exhibit for detailed clinical updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470757,"accession_number":"0001493152-26-023758","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-05-15T20:07:33+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.","R&D expenses fell 47% YoY to $1.7M; cash & marketable securities $6.3M at March 31, plus $4.4M May financing.","Successful FDA Type C meeting for LP-300 HARMONIC trial; protocol amended to focus on EGFR exon 21 L858R mutation as single-arm study.","IND cleared for Starlight Therapeutics' STAR-001 pediatric CNS cancer trial (ATRT); Rare Pediatric Disease Designations.","Launched withZeta.ai commercial AI platform; announced plan to spin it into independent entity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":445197,"accession_number":"0001493152-26-023200","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-05-14T21:26:31+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.","Unregistered warrants have exercise price $2.27, exercisable after 6 months, expire 5 years from initial exercise.","Up to additional $4.85M gross proceeds if warrants fully exercised; no assurance of exercise.","Company plans to separate AI platform withZeta.ai into independent entity; may become publicly listed.","Suspended ATM sales under July 2025 agreement with ThinkEquity; agreement remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95276,"accession_number":"0001493152-26-016047","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma demonstrates withZeta.ai AI co-scientist platform; no financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Live demo of withZeta.ai, a multi-agentic AI platform for rare cancer drug discovery and clinical design.","Presentation discussed platform capabilities, commercial architecture, rare cancer market opportunity, and competitive positioning.","Outlined near-term revenue strategy and growth roadmap for the withZeta.ai platform.","Replay of the demonstration available at provided Zoom link; presentation furnished as Exhibit 99.1.","No specific financial or operational metrics were provided in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108213,"accession_number":"0001493152-26-013608","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.","Full-year net loss $17.1M ($1.57/share) vs $20.8M ($1.93/share) in 2024; R&D expenses down 29% to $11.5M.","LP-300 HARMONIC trial: FDA Type C meeting scheduled mid-May 2026 to discuss protocol amendments focusing on EGFR exon 21 L858R patients.","LP-184 Phase 1a complete: 48% clinical benefit rate; Phase 1b/2 trials planned in TNBC, NSCLC with STK11/KEAP1 mutations.","withZeta.ai beta testing with 25+ biotech firms; company denies false report of CEO resignation, confirms Panna Sharma remains CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108212,"accession_number":"0001493152-26-003314","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma demonstrates AI tools for rare cancers at Jan 22 event","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Event hosted on Jan 22, 2026 to showcase initial AI tools and multi-agentic system for rare cancers.","Presentation furnished as Exhibit 99.1; no financial results or clinical data disclosed.","Company discusses AI-driven drug development platform, but no specific milestones or partnerships announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124648,"accession_number":"0001493152-25-022134","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.","LP-184 Phase 1a met all endpoints; 48% clinical benefit rate at therapeutic dose; RP2D set at 0.39 mg/kg.","FDA Type C meeting provides regulatory path for pediatric CNS trial in ATRT; spironolactone combo strategy confirmed.","LP-300 HARMONIC trial data presented at Japan Lung Cancer Society; Japan enrollment completed.","RADR AI platform modules commercial-ready; predictBBB 94.1% accuracy, LBx-AI 86% accuracy for treatment response."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141336,"accession_number":"0001493152-25-014652","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lantern Pharma shareholders elect all six directors, approve option repricing, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected: Keyser (2.21M for), Sharma (2.21M), Chandru (2.20M), Maccecchini (2.21M), Schalop (2.21M), Silberstein (2.21M); broker non-votes 5.19M.","One-time repricing of stock options under 2018 Equity Incentive Plan approved: 1.46M for, 759K against, 30K abstain, 5.19M broker non-votes.","Ratification of EisnerAmper LLP as auditor for FY2025 passed: 7.37M for, 44K against, 26K abstain; no broker non-votes on this item."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141335,"accession_number":"0001641172-25-023489","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantern Pharma Q2 net loss narrows to $4.33M; LP-184 Phase 1a complete, complete responses in two trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.","LP-184 Phase 1a enrollment complete (65 patients); MTD and RP2D established; advancing to Phase 1b/2 in TNBC and bladder cancer.","LP-300 HARMONIC trial shows complete response in a 70-year-old NSCLC patient who failed three prior therapies.","LP-284 achieves complete metabolic response in heavily pretreated DLBCL patient after two cycles.","Cash runway extends at least into June 2026; no quarterly earnings call planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141334,"accession_number":"0001641172-25-021407","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.","Dr. Schalop has extensive biotech and finance background including roles at Morgan Stanley, J.P. Morgan, Credit Suisse.","Board amended By-laws to reduce stockholder quorum requirement from majority to one-third (33.33%) of shares entitled to vote.","Amendment to Section 2.07 effective immediately on July 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141333,"accession_number":"0001641172-25-017810","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lantern Pharma enters $15.53M ATM equity offering agreement with ThinkEquity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM Sales Agreement allows sale of up to $15,530,000 in common stock through ThinkEquity as agent.","Agent commission set at 3.0% of gross proceeds; sales at prevailing market prices on Nasdaq.","Company has no obligation to sell any shares; agreement terminates upon full sale or earlier termination.","Offering registered under existing S-3 shelf (File No. 333-279718); prospectus supplement filed July 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159142,"accession_number":"0001641172-25-010541","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.","Net loss $4.5M ($0.42/share) vs $5.4M ($0.51/share) in Q1 2024; R&D expense $3.3M vs $4.3M.","LP-184 Phase 1a solid tumor trial enrollment expected to finish by end of June 2025; full data readout in Q3 2025.","FDA cleared Phase 1b/2 protocols for LP-184 in TNBC (with olaparib) and STK11/KEAP1-mutant NSCLC.","LP-300 HARMONIC trial additional data including Asian expansion cohort anticipated in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177604,"accession_number":"0001641172-25-000917","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.","Cash, cash equivalents and marketable securities $24.0M as of Dec 31, 2024, down from $41.3M at Dec 31, 2023.","HARMONIC trial lead-in cohort (LP-300) showed 86% clinical benefit rate and 43% ORR in never-smoker NSCLC; expansion cohort reinforcing trends.","LP-184 received two FDA Fast Track Designations (GBM, TNBC) and three Rare Pediatric Disease Designations; Phase 1a on cohort 11.","RADR platform surpassed 100B oncology data points; MD Anderson collaboration shows LP-184 synergy with anti-PD1 in TNBC preclinical models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177603,"accession_number":"0001493152-25-001685","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lantern Pharma amends CSO Bhatia's agreement: term to Jan 2026, reduced hours, $189,600 salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kishor G. Bhatia, CSO, employment term extended to January 15, 2026.","Minimum weekly hours reduced to 24 for scientific, clinical, and therapeutic development.","Annual base salary proportionately adjusted to $189,600 effective first pay period January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194308,"accession_number":"0001493152-24-044124","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q3 2024 earnings call held; no financial details in 8-K","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Conference call and live webinar occurred on November 7, 2024 for Q3 results.","Presentation covering financial and operating results furnished as Exhibit 99.1.","No specific revenue, EPS, or guidance figures were disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194307,"accession_number":"0001493152-24-044006","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.","LP-300 Harmonic trial: 86% clinical benefit rate, 43% objective response in 7-patient lead-in; expanded to Japan and Taiwan.","LP-184 Phase 1a: 9 cohorts dosed, no DLTs; FDA Fast Track for GBM; Phase 1b/2a expected early 2025.","LP-284 Phase 1a: fourth cohort dosing, no DLTs; additional hematology sites planned; potential Phase 1b/2 by mid-2025.","R&D expenses $3.7M (up from $2.2M); G&A $1.5M ($1.3M); 10.8M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210646,"accession_number":"0001493152-24-030764","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.","LP-300 Harmonic Phase 2 lead-in (7 pts): 86% clinical benefit rate, 43% objective response rate, no dose-limiting toxicities.","LP-184 Phase 1A: 7 cohorts dosed, no DLTs; LP-284 third cohort dosing, no DLTs; both on track.","RADR platform collaboration with Oregon Therapeutics for XCE853; Starlight Therapeutics advancing STAR-001 for recurrent GBM.","Japanese patent issued for LP-284; Webinar Wednesdays launched for AI and oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229010,"accession_number":"0001493152-24-024110","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five directors elected: Keyser, Sharma, Chandru, Maccecchini, Silberstein; each received ~3.04M votes for, ~22K withheld.","Amendment to 2018 Equity Incentive Plan approved to increase share pool by 125,000 shares; 2.89M for, 128K against.","Ratification of EisnerAmper LLP as independent auditor for FY2024 passed with 7.17M votes for, 40K against.","Broker non-votes of 4.23M on director election and equity plan; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229009,"accession_number":"0001493152-24-021353","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Lantern Pharma amends bylaws to streamline director count setting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors approved amendment to Section 3.02 of Bylaws on May 23, 2024, effective immediately.","Previous language required a majority of total directors (including vacancies) to set board size; now any board resolution suffices.","Authorized board size remains unchanged at minimum 3 and maximum 9 directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229008,"accession_number":"0001493152-24-018426","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma Q1 2024 net loss $5.4M, cash $38.4M; clinical trials advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.4M ($0.51/share) vs $3.9M ($0.36/share) in Q1 2023; R&D expense $4.3M vs $2.6M.","Cash, cash equivalents & marketable securities $38.4M at Mar 31, 2024, down from $41.3M at Dec 31, 2023.","Phase 1 trials for LP-184 and LP-284 continue with no dose-limiting toxicities; LP-184 enrollment to complete summer 2024.","Regulatory allowance granted to begin Phase 2 Harmonic trial in Japan and Taiwan for LP-300 in never-smoker NSCLC.","ADC program advanced: novel cryptophycin-based ADC shows picomolar potency and 80% cancer cell kill rate in preclinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247618,"accession_number":"0001493152-24-010303","cik":1763950,"company_name":"Lantern Pharma Inc.","ticker":"LTRN","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.","Cash, equivalents and marketable securities $41.3M at Dec 31, 2023, down from $55.2M a year earlier.","LP-184 Phase 1A continuing; initial readout expected late summer/early fall 2024. LP-284 Phase 1 dosed first patients.","Starlight Therapeutics hired CMO; plans Phase 1B/2 CNS trial in H2 2024. RADR platform surpassed 60B datapoints.","Share repurchase of 145,348 shares at $3.44/sh in November 2023 reduced outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39453392.45619335,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}